Evotec stock falls as 2026 guidance is cut after weak Q2 results
Published on 08/13/2026 at 15:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec SE (ISIN DE0005664809) stock is under pressure on August 13, 2026 after the Hamburg-based drug discovery specialist reported weaker second-quarter 2026 results and sharply reduced its full-year 2026 guidance, reinforcing concerns about profitability and growth momentum.
Per the company release dated August 13, 2026, Evotec reported second-quarter 2026 group revenue of €143.5 million, a decline of 16.2 percent from €171.2 million in the same period of 2025, while adjusted group EBITDA fell to a loss of €20.8 million from a loss of €5.0 million a year earlier as delayed milestone payments and slower-than-expected conversion of commercial activity into recognized revenue weighed on the business. The detailed interim report also confirms that the updated outlook for 2026 is significantly lower than the company had previously guided.
According to recent market data, Evotec shares listed on the Frankfurt Prime Standard under ticker EVT traded at €3.706 at the close on August 11, 2026, up 1.37 percent on the day, while the Nasdaq-listed American depositary shares under ticker EVO closed at $2.19 on August 12, 2026, a gain of 4.29 percent before dropping in subsequent extended trading as investors digested the weaker earnings and guidance signals. The Frankfurt quote overview and the Nasdaq price and earnings summary highlight the pressure on the stock in early August as the extent of the H1 2026 slowdown became clearer.
Guidance cut hits 2026 outlook
The sharp reduction in Evotec's full-year 2026 guidance is a key driver for the latest share price weakness, as it resets expectations for both revenue growth and profitability in the current year.
The company now expects 2026 group revenue of €570 million to €610 million, down from an earlier range of €700 million to €780 million, implying a cut of up to €210 million at the top end compared with the original target. Recent reporting on Evotec's earnings release notes that the updated guidance also projects adjusted group EBITDA for 2026 in a loss range of €70 million to €105 million, versus previous guidance that had pointed to a potential adjusted EBITDA profit of up to €40 million, marking a swing of as much as €145 million from a possible profit to a deeper loss.
This guidance revision reflects a combination of factors outlined in the interim report, including delayed milestone revenues from existing partnerships and slower-than-expected translation of commercial activity into recognized revenue, factors that particularly affected Evotec's biologics segment and certain drug discovery alliances. A summary of the related Form 6-K filing underscores that the company now anticipates weaker top-line performance and higher operating losses than previously assumed, which in turn increases the importance of execution on cost measures and pipeline milestones in the second half of 2026.
For investors, the magnitude of the guidance cut stands out: the new revenue range of €570 million to €610 million sits roughly 18 percent below the previous upper bound of €780 million, while the adjusted EBITDA range now embeds a sizeable loss rather than the earlier scenario of break-even to moderate profitability. This quantified shift shapes how the market values Evotec's medium-term prospects and raises questions about the timing of a potential return to positive earnings.
Q2 2026 earnings detail and consensus
The second-quarter and first-half 2026 results provide a detailed picture of the operational challenges behind Evotec's revised outlook, with key metrics pointing to both revenue pressure and a sharp deterioration in profitability compared with the prior year.
In Q2 2026, Evotec generated group revenue of €143.5 million, down from €171.2 million in Q2 2025, representing the 16.2 percent year-over-year decline highlighted in the earnings release. At the same time, adjusted group EBITDA declined to a loss of €20.8 million versus a loss of €5.0 million a year earlier, a deterioration of 320.3 percent that reflects higher costs and the impact of missing high-margin milestone income. The English-language earnings announcement also shows that in the first half of 2026 Evotec recorded group revenue of €300.1 million, compared with €313.2 million at constant currency and a prior-year level cited in the report, while adjusted EBITDA stood at a loss of €42.7 million for H1 2026, highlighting a sustained negative trend.
On the earnings per share line, Evotec reported Q2 2026 EPS of -$0.14 for its Nasdaq-listed shares, missing the consensus estimate of -$0.05 by $0.09. The earnings overview notes that this miss relative to expectations adds to the pressure from the guidance reduction, as it suggests that both near-term profitability and longer-term targets are under strain. The combination of weaker revenue, substantially lower EBITDA, and an EPS miss sends a clear signal that Evotec's current business mix and cost structure are not yet aligned with its growth ambitions.
Segment data in the interim report show that the Just - Evotec Biologics division generated Q2 2026 revenue of €35.4 million, which represents a 17.4 percent decline compared with the prior-year quarter. The segment's adjusted EBITDA was negative at €6.2 million, reinforcing the view that this biologics business, while strategic for Evotec's long-term positioning in complex biologic therapies, remains in an investment-heavy phase and is not yet contributing positive earnings to offset the volatility of milestone-driven revenues.
Share price reaction and SDax context
Evotec's share-price reaction in local trading reflects the disappointment embedded in the earnings and guidance update, with the stock moving lower on August 13, 2026 despite having shown some resilience in the sessions immediately preceding the release.
A market overview from the German mid-cap index segment indicates that Evotec shares in the SDax fell by around 1 percent to €3.81 in midday trading on August 13, 2026, making the stock one of the weaker performers in the index on the day the finalized half-year figures were presented. The intraday commentary ties this share-price decline directly to the publication of the completed H1 2026 report and the confirmation of the lower full-year guidance.
Looking beyond the single trading session, the combination of a Q2 revenue decline of 16.2 percent, a 320.3 percent deterioration in adjusted EBITDA, and a full-year revenue guidance range that sits substantially below the earlier target helps explain why Evotec's share price has struggled to gain traction. Investors evaluating the stock within the SDax universe must weigh the attractive long-term prospects of Evotec's drug discovery and development platform against the more immediate reality of lower near-term earnings and the need for disciplined cost and capital management.
At the same time, the earnings and guidance update provides some clarity by resetting expectations and anchoring valuation discussions around a revised revenue range of €570 million to €610 million and an adjusted EBITDA loss of €70 million to €105 million in 2026. For investors, those numbers are central reference points when considering potential recovery scenarios, as they define the base from which any upside in 2027 and beyond would need to be built.
Strategic alliances and pipeline support
Despite the weaker near-term financial performance, Evotec continues to highlight its strategic alliances and pipeline as key pillars that can support long-term value creation, particularly in complex areas such as protein degradation and biologics.
A key example is Evotec's extended alliance with Bristol Myers Squibb's Celgene unit focused on protein degraders, where the partner has committed an additional $200 million to expand the collaboration and increased the potential deal value to up to $5 billion. A recent report on the alliance notes that Bristol Myers Squibb has been impressed by the progress achieved in the first four years of the partnership and is prepared to extend the collaboration for eight more years, reinforcing the strategic importance of Evotec's expertise in molecular glue degraders and targeted protein degradation.
For investors, such alliances offer two important forms of support. First, they provide upfront and milestone payments that can help diversify revenue away from pure fee-for-service discovery activities, and second, they validate Evotec's scientific capabilities in areas where large pharma partners are actively seeking innovation. The expanded Bristol Myers Squibb alliance, with its potential multibillion-dollar value, illustrates how Evotec can plug into larger pharma companies' pipelines and shape the development of next-generation therapies.
Nevertheless, the Q2 2026 numbers show that even with strategic alliances in place, the timing of milestones and revenue recognition can be uneven, underscoring the need for a more balanced mix of recurring revenues and partnership income. The 16.2 percent year-over-year decline in group revenue and the sharp increase in adjusted EBITDA losses highlight how sensitive Evotec's financials remain to delays in milestone flows and the ramp-up of newer businesses such as Just - Evotec Biologics.
Representative product and services platform
Evotec's business model revolves around an integrated drug discovery and development platform that combines high-throughput screening, medicinal chemistry, biologics capabilities, and translational research to support both internal projects and partnerships with pharma and biotech companies.
A representative offering is the Just - Evotec Biologics platform, which provides end-to-end biologics design, development, and manufacturing services. According to the interim report, this division generated Q2 2026 revenue of €35.4 million and saw a 17.4 percent decline versus the prior-year quarter, but remains central to Evotec's strategy of building a scalable biologics infrastructure capable of supporting complex antibody and protein therapeutics from early discovery through to clinical supply. Clients use this platform to optimize biologic constructs for manufacturability and efficacy, leveraging Evotec's expertise in computational design and process development.
In drug discovery, Evotec offers integrated solutions that span target identification, hit finding, lead optimization, and preclinical development, using a combination of proprietary technologies and deep disease-area expertise. These services underpin collaborations like the Bristol Myers Squibb protein degrader alliance and other partnerships in areas such as neuroscience, oncology, and metabolic diseases, where Evotec's platform aims to accelerate the discovery of novel small-molecule and biologic therapies.
For retail investors, the key takeaway from this product and services profile is that Evotec's revenue base depends heavily on the success and continuity of such partnerships, as well as on the ramp-up of newer platforms like Just - Evotec Biologics. The Q2 2026 numbers, with a double-digit revenue decline and a deeper EBITDA loss, show that while the scientific platforms remain attractive, the financial translation into consistent revenue and profit growth is still a work in progress.
Evotec stock and current market values
Evotec shares trade in both Europe and the United States, giving investors access to the company through the Frankfurt Prime Standard listing under ticker EVT and the Nasdaq listing under ticker EVO.
As of the close on August 11, 2026, Evotec's Frankfurt-listed shares changed hands at €3.706, representing a gain of 1.37 percent on that trading day, while the Nasdaq-listed American depositary shares closed at $2.19 on August 12, 2026, up 4.29 percent before moving lower in extended trading as the Q2 2026 results and guidance cut were digested. These price points place the stock in the lower single-digit range on both exchanges, underscoring how the market has adjusted its valuation in response to the weaker financial performance and reduced outlook.
For investors tracking Evotec stock, the current numbers that matter most are the Q2 2026 revenue of €143.5 million with a 16.2 percent year-over-year decline, the adjusted EBITDA loss of €20.8 million which deteriorated 320.3 percent from the prior-year quarter, and the 2026 revenue guidance range of €570 million to €610 million accompanied by an adjusted EBITDA loss forecast of €70 million to €105 million. Together, these metrics frame the risk and opportunity profile of Evotec shares over the coming quarters and help investors decide whether the long-term pipeline and partnership potential compensate for the near-term earnings pressure and guidance reset.
Fact box
Company: Evotec SE
ISIN: DE0005664809
Ticker: EVT (Frankfurt), EVO (Nasdaq)
Exchange: Frankfurt Prime Standard, Nasdaq
Sector / Industry: Biotechnology, drug discovery and development services
Index membership: SDax
